Skip to main content
Article
Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Dawn of a New Era
Postgraduate Medicine
  • Tahmeed Contractor, MD, Lehigh Valley Health Network
  • Vadim Levin, MD, Lehigh Valley Health Network
  • Matthew W Martinez, Lehigh Valley Health Network
  • Francis E Marchinski, MD
Publication/Presentation Date
1-1-2013
Abstract
Atrial fibrillation (AF) is an important cause of ischemic stroke and is the underlying cause of > 20% of all strokes, with increasing age being a risk factor. Until recently, warfarin was the only available oral anticoagulant used to decrease this risk in patients with AF. However, there are several disadvantages of warfarin use, such as the requirement for monitoring the international normalized ratio, its wide range of drug-food interactions, and its narrow therapeutic index. Thus, there has been a strong impetus for the development of newer oral anticoagulants with predictable pharmacokinetics that obviate the need for monitoring the international normalized ratio. The US Food and Drug Administration has approved a direct thrombin inhibitor (dabigatran) and 2 factor Xa inhibitors (rivaroxaban and apixaban) for stroke prevention in patients with nonvalvular AF. There are several other new oral anticoagulant agents on the horizon, including the factor Xa inhibitor edoxaban. This review article discusses the pharmacological properties, clinical trial data, and practical issues associated with the use of these novel oral anticoagulants.
PubMedID
23391669
Document Type
Article
Citation Information

Contractor, T., Levin, V., Martinez, M. W., & Marchlinski, F. E. (2013). Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Postgraduate Medicine, 125(1), 34-44. doi:10.3810/pgm.2013.01.262.